COMPANY PROFILE

VentiRx Pharmaceuticals

Development and commercialization of novel Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases

Seattle, United StatesFounded 2006Biotech & Life Sciences

Valuation $250–500M Last recorded · 2014

Total funding $100–500M Disclosed equity funding

Unlock exact values

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals is a biopharmaceutical company dedicated to the development of novel immunotherapies for the treatment of cancer and inflammatory diseases. The company primarily serves patients and healthcare providers, operating in the biotechnology and pharmaceutical markets. VentiRx's business model revolves around research and development (R&D) of proprietary drug candidates, which are then advanced through clinical trials. The company generates revenue through partnerships, licensing agreements, and potential future sales of approved therapies.

VentiRx focuses on leveraging its expertise in immunology to create therapies that harness the body's immune system to fight diseases. The company collaborates with academic institutions, research organizations, and other biotech firms to accelerate the development of its drug candidates.

Key revenue streams include milestone payments from partners, research grants, and eventual commercialization of successful therapies. VentiRx aims to address unmet medical needs and improve patient outcomes through innovative treatment options.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: Seattle, United States
Open positions: None listed
Dealroom signal: 56.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Sep 2014	$51M	$202M	MedImmune Ventures · ARCH Venture Partners · Celgene · Frazier Healthcare Partners	—
SERIES AOther financing	Jan 2010	$25M	$100M	MedImmune Ventures	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

VentiRx Pharmaceuticals website traffic

Latest recorded traffic for VentiRx Pharmaceuticals is 0 monthly website visits.

Latest monthly visits0

Monthly website visitsApr 2016–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
IPISA PharmaceuticalsDeveloping rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections	Leiden, Netherlands	Closed	5	$37M	$114M
COCoridonCoridon develops DNA therapies for the prevention and treatment of viral infections, and therapeutic vaccines for the treatment of cancer	Brand, Austria	Operational
BIBiotheraBiotechnology company developing natural gluco polysaccharides that engage and direct natural innate immune systems	Eagan, United States	Operational
ETEureka TherapeuticsBiotechnology company focuses on an immunotherapies for the treatment of cancer	Emeryville, United States	Operational
ITIGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors	London, United Kingdom	Operational
IPIndex PharmaceuticalsDeveloping drugs to treat inflammatory bowel disease that can help patients return to a normal life	Solna kommun, Sweden	Operational
CPCorvus PharmaceuticalsClinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer	Burlingame, United States	Operational
MAMelanoma Research AllianceThe Melanoma Research Alliance exists to accelerate treatment options and find a cure for melanoma	United States	Operational